A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase

Su Jong Yu1,*, Jae-Kyung Won2,3,4,*, Han Suk Ryu4, Won-Mook Choi1, Hyeki Cho1, Eun-Ju Cho1, Jeong-Hoon Lee1, Yoon Jun Kim1, Kyung-Suk Suh2, Ja-June Jang4, Chung Yong Kim1, Hyo-Suk Lee1, Jung-Hwan Yoon1, and Kwang-Hyun Cho2,3

Background/Aims: Protein disulfide isomerase (PDI) has been implicated in the survival and progression of some cancer cells, by compensating for endoplasmic reticulum stress by upregulating the protein-folding capacity. However, its prognostic role in patients with hepatocellular carcinoma (HCC) has not been investigated.

Methods: We collected HCC tissues from 83 HCC patients who underwent surgical resection for an immunohistochemical study of PDI. Overall survival (OS) was measured from the date of surgical resection until the date of death from any cause. Radiological progression was evaluated using the modified Response Evaluation Criteria in Solid Tumors in an independent radiological assessment.

Results: PDI expression was found to be increased in human HCC compared to adjacent nontumor tissues. Increased immunopositivity for PDI was associated with a high Edmondson-Steiner grade (p = 0.028). Univariate analysis of patients who had undergone surgical resection for HCC showed that tumor PDI upregulation is a significant risk factor for poor OS (p = 0.016; hazard ratio [HR], 1.980) and time to progression (TTP; p = 0.007; HR, 1.971). Multivariate analyses revealed that high PDI expression was an independent predictor of a shorter TTP (p = 0.015; HR, 1.865) and poor OS (p = 0.012; HR, 2.069).

Conclusions: Upregulated PDI expression is associated with aggressive clinicopathological features of HCC; thus, PDI might serve as an independent prognostic factor and a potential therapeutic target for HCC patients.

Keywords: Protein disulfide isomerase; Endoplasmic reticulum stress; Carcinoma, hepatocellular; Prognosis

INTRODUCTION

Hepatocellular carcinoma (HCC) is the fifth-leading cause of cancer-related death worldwide [1]. Curative resection is the primary therapeutic modality for HCC, except in advanced cases, but the prognosis of individual patients varies and several molecular markers of the prognosis of HCC have been identified [2]. Unfortunately, few molecular markers for HCC are targetable by drugs and there is a pressing need to identify new molecular candidates to improve therapeutic strategies and predict the prognosis in the era of targeted an-
ti-cancer therapy.

Protein disulfide isomerase (PDI) is a 57-kDa dithi-ol:disulfide oxidoreductase and molecular chaperone. It is one of the most abundant soluble proteins in the endoplasmic reticulum (ER) and plays a key role in maintaining cellular homeostasis by mediating oxidative protein folding [3]. PDI expression is upregulated in some cancer types and involved in aggressive phenotypes of breast [4], brain [5], ovary [6], and prostate [7] cancers. Increasing evidence from functional studies indicates that PDI has an important role in tumor survival and cancer progression [3]. In human HCC cell lines, PDI was expressed in a hypoxia-inducible manner [8]. However, the expression of PDI in human HCC tissues and its prognostic role in patients with HCC has not been determined.

This study investigated whether PDI is expressed in human HCC tissues and evaluated the effect of PDI expression on the time to progression (TTP) and overall survival (OS) after surgical resection in patients with HCC. We found that PDI expression was upregulated in HCC samples and that high PDI expression was an independent predictor of a poor prognosis.

METHODS

Study population
Tissue specimens were collected from 83 patients with HCC resected between 2004 and 2012 at Seoul National University Hospital (SNUH). The histopathological features were evaluated retrospectively from hematoxylin-and-eosin-stained slides, and clinical and follow-up data were obtained from the medical records. Histological grade was scored according to the Edmonson-Steiner grading system [9], and pathological staging (pT stage) was determined according to the American Joint Committee on Cancer grading system (7th edition) [10]. The main clinical and pathological variables evaluated in this study are shown in Table 1. This study was conducted with the approval of the Institutional Review Board of SNUH, with waiver of the requirement for informed consent.

Tissue microarray construction
Previously stained hematoxylin and eosin slides were reviewed retrospectively, and more than two representative formalin-fixed, paraffin-embedded archival blocks were selected per case. Tissues from adjacent nontumor areas were also collected. The arrays were assembled by taking core tissue biopsies (5 mm in diameter) from specific locations in the existing formalin-fixed, paraffin-embedded blocks (donor blocks) and re-embedding them in recipient paraffin blocks (tissue array blocks) using a trephine.

Immunohistochemical staining
Immunohistochemical staining using an anti-PDI rabbit polyclonal antibody (Catalogue No. 2446, 1:100 dilution, Cell Signaling Technology, Danvers, MA, USA) was performed on tissue array slides using the Ventana OptiView system (Roche Diagnostics, Mannheim, Germany).

Evaluation of immunohistochemical staining
The immunohistochemical staining was analyzed independently by two qualified pathologists. A semiquantitative scoring system was used to evaluate PDI expression using both the intensity of cytoplasmic staining (3, strong; 2, intermediate; 1, weak) and percentage of positive cells (1, ≤ 25%; 2, 25% to 75%; 3, > 75%). If there were differences in the initial evaluation, the slides were reviewed to achieve consensus. Cases with total scores of 2 to 4 and 5 to 6 were classified as the low- and high-expression groups, respectively.

Statistical analysis
Continuous variables were compared using Student t test and dichotomous variables using the chi-square test. Survival time was measured from the date of surgical resection to the date of death or last contact. Conventional clinical variables at the time of entry into the study and immunopositivity for PDI were analyzed to identify factors that influenced survival, as determined using the Kaplan-Meier method and compared using the log-rank test. Stepwise, univariate, and multivariate analyses were performed using the Cox proportional hazards model to identify factors that influenced survival. Variables found to be significantly associated with the outcome in the univariate analyses were included in the multivariate analysis. All statistical analyses were performed using SPSS version 19.0 (IBM Co., Armonk,
NY, USA), and $p$ values < 0.05 were considered to indicate significance.

RESULTS

PDI expression in HCC and nonneoplastic hepatic tissues
First, we investigated whether PDI expression is increased in HCC compared to nontumor tissue. PDI protein expression was evaluated in tumor areas and adjacent nontumor areas in each patient in our study population. The immunohistochemical analysis of the 83 HCC patients indicated that PDI expression was increased in the tumor tissue of 51 cases (61.4%) compared to nearby nontumor tissue, whereas 11 cases (13.3%) showed a decrease in PDI expression compared to adjacent nontumor tissue ($p < 0.0001$) (Fig. 1).

Correlations between PDI expression status and clinicopathological variables
To determine the clinical significance of the PDI level in HCC, we assessed the correlation between PDI expression in the tumor and various clinicopathological variables (Table 1). Classifying the tumors into high- and low-expression groups, high PDI expression was significantly correlated with a high Edmonson-Steiner grade ($p = 0.028$), but not with gender, age, etiology, $\alpha$-fetoprotein (AFP) level, Child-Pugh class, tumor size, tumor multiplicity, vascular invasion, or lymph node metastasis (Table 1).

Prognostic significance of PDI expression in patients with HCC
To evaluate the prognostic significance of PDI expression, univariate analyses of TTP and OS were performed. As shown in Fig. 2, the high-PDI-expression group had a significantly shorter TTP and poorer OS

Figure 1. Protein disulfide isomerase (PDI) expression levels increased with the development of hepatocellular carcinoma (HCC). (A) Low expression in adjacent non-tumoral tissue ($\times100$). (B) High expression in HCC tissue in the same patient ($\times100$). (C) The proportion of the relative changes in PDI expression compared to adjacent non-tumoral tissue ($p < 0.0001$).
than the low-PDI-expression group ($p = 0.007$ and $p = 0.016$, respectively). The AFP level, tumor size, and tumor multiplicity also differed significantly for TTP ($p = 0.002$, $p = 0.001$, and $p = 0.025$, respectively), while tumor size, tumor multiplicity, and Edmondson-Steiner histological grade had prognostic significance for OS ($p = 0.024$, $p = 0.046$, and $p = 0.002$, respectively) (Table 2).

We performed a multivariate Cox regression analysis to investigate whether PDI expression was an independent predictor of TTP and OS. PDI expression was an independent predictor of tumor recurrence ($p = 0.015$). Large tumor size was also an independent predictor of TTP ($p = 0.017$) (Table 3). For OS, because histological grade was associated with PDI expression in our correlation study, we included PDI expression in the multivariate analysis to avoid any bias caused by multlinearity. Indeed, PDI expression was found to be an independent predictor of OS ($p = 0.012$) (Table 4).

### Table 1. The correlation between PDI expression and clinicopathologic variables in this study

| Clinicopathologic variable | Number | PDI high, n (%) | PDI low, n (%) | $p$ value |
|---------------------------|--------|----------------|---------------|----------|
| **Gender**                |        |                |               |          |
| Male                      | 71     | 44 (86.3)      | 27 (87.1)     | 0.811    |
| Female                    | 12     | 8 (13.7)       | 4 (12.9)      |          |
| **Age, yr**               |        |                |               |          |
| ≤ 55                      | 45     | 27 (52.9)      | 18 (56.2)     | 0.768    |
| > 55                      | 38     | 24 (47.1)      | 14 (43.8)     |          |
| **Etiology**              |        |                |               |          |
| Non-viral                 | 11     | 9 (17.6)       | 2 (6.2)       | 0.190    |
| Viral                     | 72     | 42 (82.4)      | 30 (93.8)     |          |
| **AFP level, ng/mL**      |        |                |               |          |
| ≤ 200                     | 45     | 17 (54.8)      | 28 (54.9)     | 1.000    |
| > 200                     | 38     | 15 (45.2)      | 23 (45.1)     |          |
| **Child-Pugh classification** |    |                |               |          |
| A                         | 76     | 47 (92.2)      | 29 (90.6)     | 1.000    |
| B&C                       | 7      | 4 (7.8)        | 3 (9.4)       |          |
| **Tumor size, cm**        |        |                |               |          |
| ≤ 5                       | 32     | 22 (43.1)      | 10 (31.2)     | 0.279    |
| > 5                       | 51     | 29 (56.9)      | 22 (68.8)     |          |
| **Tumor number**          |        |                |               |          |
| Single                    | 41     | 26 (61.0)      | 15 (46.9)     | 0.716    |
| Multiple                  | 42     | 25 (49.0)      | 17 (33.3)     |          |
| **Edmondson grade (worst)** |     |                |               |          |
| Grade 1–3                 | 38     | 28 (56.0)      | 10 (31.2)     | 0.028    |
| Grade 4                   | 44     | 22 (44.0)      | 22 (68.8)     |          |
| **Vascular invasion**     |        |                |               |          |
| Absent                    | 31     | 21 (41.2)      | 10 (31.2)     | 0.363    |
| Present                   | 52     | 30 (58.8)      | 22 (68.8)     |          |
| **Lymph node metastasis** |        |                |               |          |
| Absent                    | 66     | 41 (61.7)      | 25 (78.1)     | 0.803    |
| Present                   | 17     | 10 (58.8)      | 7 (41.2)      |          |

PDI, protein disulfide isomerase; AFP, α-fetoprotein.

http://dx.doi.org/10.3904/kjim.2014.29.5.580
Figure 2. Protein disulfide isomerase (PDI) expression levels significantly associated with time to progression (TTP) and overall survival (OS). (A) TTP rate ($p = 0.007$). (B) OS rate between PDI low expression group and PDI high expression group ($p = 0.016$).

Table 2. Univariate analysis of time to progression and overall survival in this study population

| Variable                      | Number | Time to progression | Overall survival |
|-------------------------------|--------|---------------------|------------------|
|                               |        | HR (95% CI)         | p value          |
|                               |        | HR (95% CI)         | p value          |
| Etiology                      | 72     | 0.618 (0.316–1.211) | 0.161            |
| AFP level, ng/mL              | 38     | 2.089 (1.314–3.323) | 0.002            |
| > 200                         | 1.540 (0.931–2.550) | 0.093            |
| Child-Pugh class              | 7      | 0.795 (0.365–1.734) | 0.564            |
| Tumor size, cm                | 51     | 2.403 (1.466–3.939) | 0.001            |
| > 5                           | 1.840 (1.084–3.123) | 0.024            |
| Tumor multiplicity            | 42     | 1.668 (1.066–2.612) | 0.025            |
| Multiple                      | 44     | 1.050 (0.671–1.643) | 0.830            |
| Histologic grade              | 44     | 2.368 (1.379–4.064) | 0.002            |
| Grade 4                       | 44     | 2.368 (1.379–4.064) | 0.002            |
| Vascular invasion             | 52     | 1.556 (0.976–2.749) | 0.063            |
| Present                       | 52     | 1.451 (0.859–2.449) | 0.164            |
| Lymph node metastasis         | 5      | 1.206 (0.484–3.003) | 0.687            |
| Present                       | 5      | 1.868 (0.740–4.718) | 0.186            |
| PDI expression                | 32     | 1.971 (1.203–3.230) | 0.007            |
| High                          | 32     | 1.980 (1.134–3.457) | 0.016            |

HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein; PDI, protein disulfide isomerase.
DISCUSSION

This study found that the expression of PDI was increased in HCC compared to nontumor tissue and that increased expression was associated with the aggressive clinicopathological features of HCC. Moreover, upregulated PDI expression in HCC tissues was an independent risk factor for a poor OS and shorter TTP in patients with HCC. This is the first report that the level of PDI expression adversely affects the OS and progression of HCC patients who have undergone surgical resection.

One can argue that the increased PDI level is a by-product of cancer, such as the cellular environment, disease progression status, or degree of tumor differentiation. However, recent studies indicate that PDI is important for tumor survival and progression, emphasizing its role as a tumor-promoting factor [5,11-13]. PDI expression seems to be associated with protection of cancer cells from proteotoxic stress and hypoxic damage. Hypoxia can induce the accumulation of unfolded or misfolded proteins and lead to ER-stress-induced cell death [14]. Altered ER function results in ER stress and subsequent activation of the unfolded protein response (UPR), an important ER stress response that protects the cell by removing unfolded or misfolded proteins [15]. PDI proteins are key molecules in the UPR. Many ER-stress-response chaperones have PDI activity or PDI-like domains; therefore, blocking this activity might increase ER stress and enhance apoptosis [16].

Locally recurrent HCC nodules that survive hypoxic insults after transarterial chemoembolization sometimes have significantly shorter doubling times than those in neighboring nodules [17]. Moreover, HCC sometimes undergoes an infiltrating rather than a mass-forming growth pattern; these advanced infiltrative HCCs seldom show hypervascularity, grow more rapidly, and have a poorer prognosis than the mass-forming hypervascular types. These findings suggest that hypoxia activates the signals that allow HCC cells to survive and proliferate [18] and that PDI contributes to the survival and progression of these cancer cells. This explains the correlation between PDI expression and an aggressive cancer phenotype.

The expression of PDI family proteins, an important arm of the UPR, correlates with cancer invasion, metastasis, and drug resistance in various tumor types, including melanomas and gliomas [5,11]. UPR, a prosurvival pathway that is activated during hypoxia, which is a hallmark of solid tumors [19], is also an important mediator of metastasis in human cervical cancer [20]. UPR promoted the polarization of tumor-infiltrating myeloid cells toward an inflammatory/immunosuppressive phenotype, leading to T-cell dysfunction and, ultimately, to the evasion of tumor cells from immuno-
The expression of protein disulfide isomerase (PDI) was increased in hepatocellular carcinoma (HCC) tissues compared to adjacent nontumor tissues.

2. The level of PDI expression was significantly associated with the Edmondson-Steiner grade.

3. Univariate and multivariate analyses revealed that high PDI expression was an independent predictor of a shorter time to progression and poorer overall survival of HCC patients who underwent surgical resection.

Conflict of interest
No potential conflict of interest relevant to this article was reported.

Acknowledgments
This study was supported by National Research Foundation of Korea grants funded by the Ministry of Science, ICT and Future Planning (2010-0017662 and 2013M3A9A7046903). It was also supported by grants from the SNUH Research Fund (No. 04-2011-0660) and the Liver Research Foundation of Korea.

REFERENCES
1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004;130:497-513.
3. Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discov Today 2014;19:222-240.
4. Lee HH, Lim CA, Cheong YT, Singh M, Gam LH. Comparison of protein expression profiles of different stages of lymph nodes metastasis in breast cancer. Int J Biol Sci
Yu SJ, et al. Protein disulfide isomerase for HCC

2012;8:353-362.

5. Goplen D, Wang J, Enger PO, et al. Protein disulfide
isomerase expression is related to the invasive properties
of malignant glioma. Cancer Res 2006;66:985-9902.

6. Xu S, Butkevich AN, Yamada R, et al. Discovery of an orally
active small-molecule irreversible inhibitor of protein
disulfide isomerase for ovarian cancer treatment. Proc
Natl Acad Sci U S A 2012;109:16948-16953.

7. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological
targets in prostate cancer. Cancer Res 2001;61:5974-5998.

8. Yu SJ, Yoon JH, Yang JI, et al. Enhancement of hexokinase
II inhibitor-induced apoptosis in hepatocellular carcinoma
cells via augmenting ER stress and anti-angiogenesis
by protein disulfide isomerase inhibition. J Bioenerg Biomembr 2012;44:101-115.

9. Shin E, Yu YD, Kim DS, Won NH. Adiponectin receptor
expression predicts favorable prognosis in cases of hepa-
tocellular carcinoma. Pathol Oncol Res 2014;20:667-675.

10. Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, Lu SN.
Validation of the 7th edition TNM staging system for hepa-
tocellular carcinoma: an analysis of 8,828 patients in a
single medical center. Dig Dis Sci 2013;58:2721-2728.

11. Tager M, Kroning H, Thiel U, Ansorge S. Membrane-bound
proteindisulfide isomerase (PDI) is involved in regulation
of surface expression of thiols and drug sensitivity of
B-CLL cells. Exp Hematol 1997;25:601-607.

12. Sipes NJ, Miller DA, Bascom CC, Winkler JK, Matrisian
LM, Moses HL. Altered regulation of protein disulfide
isomerase in cells resistant to the growth-inhibitory ef-
fects of transforming growth factor beta 1. Cell Growth
Differ 1990;1:241-246.

13. Lovat PE, Corazzari M, Armstrong JL, et al. Increasing
melanoma cell death using inhibitors of protein disulfide
isomerases to abrogate survival responses to endoplasmic
reticulum stress. Cancer Res 2006;66:5363-5369.

14. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticu-
llum stress: cell life and death decisions. J Clin Invest
2005;115:2656-2664.

15. Szegedi E, Logue SE, Gorman AM, Samali A. Mediators
of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 2006;7:880-885.

16. Puig A, Lyles MM, Noiva R, Gilbert HF. The role of the
thiol/disulfide centers and peptide binding site in the
chaperone and anti-chaperone activities of protein disul-
fdie isomerase. J Biol Chem 1994;269:19128-19135.

17. Tezuka M, Hayashi K, Kubota K, et al. Growth rate of lo-
caly recurrent hepatocellular carcinoma after transcath-
ether arterial chemoembolization: comparing the growth
rate of locally recurrent tumor with that of primary hepa-
tocellular carcinoma. Dig Dis Sci 2007;52:783-788.

18. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores
GJ. Hypoxia stimulates proliferation of human hepatoma
cells through the induction of hexokinase II expression. J
Hepatol 2005;42:358-364.

19. Rapisarda A, Melillo G. Role of the hypoxic tumor micro-
environment in the resistance to anti-angiogenic thera-
pies. Drug Resist Updat 2005;12:74-80.

20. Mujic H, Nagelkerke A, Rouschop KM, et al. Hypoxic
activation of the PERK/eIF2alpha arm of the unfolded
protein response promotes metastasis through induction
of LAMP3. Clin Cancer Res 2013;19:6126-6137.

21. Mahadevan NR, Rodvold JJ, Zanetti M. A Janus-faced role
of the unfolded protein response in antitumor immuni-
tity. Oncoimmunology 2013;2:e23901.

22. Finn OJ. Immuno-oncology: understanding the function
and dysfunction of the immune system in cancer. Ann
Oncol 2012;23 Suppl 8:viii6-viii9.

23. Feng Y, Tian ZM, Wan MX, Zheng ZB. Protein profile of
human hepatocarcinoma cell line SMMC-7721: identifi-
cation and functional analysis. World J Gastroenterol
2007;13:2608-2614.

24. Chignard N, Shang S, Wang H, et al. Cleavage of endo-
plasmic reticulum proteins in hepatocellular carcinoma:
detection of generated fragments in patient sera. Gastro-
enterology 2006;130:2016-2022.

http://dx.doi.org/10.3904/kjim.2014.29.5.580

www.kjim.org